Boston, MA, United States of America

Ciric To

USPTO Granted Patents = 3 

 


Average Co-Inventor Count = 9.8

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Ciric To in Cancer Research

Introduction

Ciric To is a prominent inventor based in Boston, MA, recognized for his contributions to the field of cancer research. He holds a patent that is crucial in the development of targeted therapies for diseases where the epidermal growth factor receptor (EGFR) plays a significant role. With a mission to enhance treatment options, Ciric To's work exemplifies the intersection of innovation and healthcare.

Latest Patents

Ciric To has been granted a patent for "Inhibitors of EGFR and methods of use thereof." This patent involves a compound represented by Formula Ia or Ib, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. The compound is designed to modulate the activity of EGFR, leading to potential therapeutic applications in treating or preventing diseases associated with this receptor. This innovative approach aims to provide more effective treatment options in oncology.

Career Highlights

Ciric To is associated with the Dana-Farber Cancer Institute Inc., where he utilizes his expertise to advance cancer research. His work primarily focuses on developing novel pharmaceutical compositions that can significantly impact patient outcomes. The institute is renowned for its dedication to cancer treatment and research, allowing Ciric to collaborate with leading experts in the field.

Collaborations

Throughout his career, Ciric To has collaborated with several esteemed colleagues, including Nathanael Schiander Gray and Dries De Clercq. These partnerships reflect a vibrant exchange of ideas and expertise, fostering an environment conducive to groundbreaking discoveries in cancer therapies.

Conclusion

Ciric To's innovative contributions to cancer research illustrate the importance of targeted therapies in improving treatment outcomes. With a specific focus on EGFR modulation, his patent marks a significant advancement in the fight against cancer. As researchers like Ciric continue to push the boundaries of science, the hope for more effective treatments becomes increasingly tangible.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…